Literature DB >> 29667224

Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management.

Min Dong1,2, Patrick T McGann3,2, Tomoyuki Mizuno1, Russell E Ware3,2, Alexander A Vinks1,2.   

Abstract

Entities:  

Keywords:  Bayes; Bayesian individualized dosing; hydroxycarbamide; hydroxyurea; population PK model

Mesh：

Substances：

Year:  2018        PMID： 29667224      PMCID： PMC6005594          DOI： 10.1111/bcp.13585

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  13 in total

1.  Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-08-01       Impact factor: 4.009

Review 2.  Opportunities for model-based precision dosing in the treatment of sickle cell anemia.

Authors:  Min Dong; Tomoyuki Mizuno; Alexander A Vinks
Journal:  Blood Cells Mol Dis       Date:  2017-08-09       Impact factor: 3.039

3.  Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.

Authors:  Russell E Ware; Jenny M Despotovic; Nicole A Mortier; Jonathan M Flanagan; Jin He; Matthew P Smeltzer; Amy C Kimble; Banu Aygun; Song Wu; Thad Howard; Alex Sparreboom
Journal:  Blood       Date:  2011-08-29       Impact factor: 22.113

4.  Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia.

Authors:  Jeremie H Estepp; Chiara Melloni; Courtney D Thornburg; Paweł Wiczling; Zora Rogers; Jennifer A Rothman; Nancy S Green; Robert Liem; Amanda M Brandow; Shelley E Crary; Thomas H Howard; Maurine H Morris; Andrew Lewandowski; Uttam Garg; William J Jusko; Kathleen A Neville
Journal:  J Clin Pharmacol       Date:  2015-10-15       Impact factor: 3.126

5.  Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.

Authors:  Min Dong; Patrick T McGann; Tomoyuki Mizuno; Russell E Ware; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2016-02-05       Impact factor: 4.335

6.  Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease.

Authors:  Paweł Wiczling; Robert I Liem; Julie A Panepinto; Uttam Garg; Susan M Abdel-Rahman; Gregory L Kearns; Kathleen A Neville
Journal:  J Clin Pharmacol       Date:  2014-04-11       Impact factor: 3.126

7.  Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.

Authors:  Jeremie H Estepp; Paweł Wiczling; Joseph Moen; Guolian Kang; Joana Marie Mack; Robert Liem; Julie A Panepinto; Uttam Garg; Gregory Kearns; Kathleen A Neville
Journal:  Br J Clin Pharmacol       Date:  2017-11-28       Impact factor: 4.335

Review 8.  Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control.

Authors:  R W Jelliffe; A Schumitzky; M Van Guilder; M Liu; L Hu; P Maire; P Gomis; X Barbaut; B Tahani
Journal:  Ther Drug Monit       Date:  1993-10       Impact factor: 3.681

Review 9.  Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.

Authors:  A S Darwich; K Ogungbenro; A A Vinks; J R Powell; J-L Reny; N Marsousi; Y Daali; D Fairman; J Cook; L J Lesko; J S McCune; Caj Knibbe; S N de Wildt; J S Leeder; M Neely; A F Zuppa; P Vicini; L Aarons; T N Johnson; J Boiani; A Rostami-Hodjegan
Journal:  Clin Pharmacol Ther       Date:  2017-04-04       Impact factor: 6.875

10.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.

Authors:  Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971
View more
  1 in total

1.  Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management.

Authors:  Min Dong; Patrick T McGann; Tomoyuki Mizuno; Russell E Ware; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2018-04-17       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.